

**Minimal Residual Disease (MRD) as a Surrogate Endpoint
in Acute Lymphoblastic Leukemia (ALL) Workshop
Meeting Roster
April 18, 2012**

FDA White Oak Campus, Building 31, the Great Room,
White Oak Conference Center
(Rm. 1503), Silver Spring, MD

PANELISTS

Adam Bagg, M.D.

Professor of Pathology and Laboratory Medicine
Director, Hematology
Medical Director, Clinical Cancer Cytogenetics
University of Pennsylvania

Andrea Biondi, M.D.

Professor of Pediatrics at the Faculty of Medicine and Surgery, University of Milano-Bicocca
Director of the Department and the School of Pediatrics, University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy
Head of the M. Tettamanti Research Center and S. Verri Cellular and Gene Therapy Laboratory,
San Gerardo Hospital, Monza, Italy

Rita Braziel, M.D.

Medical Director, Hematopathology
Oregon Health and Science University

Giovanni Cazzaniga, Ph.D.

Senior Scientist
M. Tettamanti Research Center
Department of Pediatrics
University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy

Meenkashi Devidas, Ph.D.

Research Associate Professor, Department of Biostatistics
Co-Director, Children's Oncology Group Statistics and Data Center, University of Florida site
Lead Statistician, Children's Oncology Group Acute Lymphoblastic Leukemia Disease Committee
Associate Program Director, Children's Oncology Group

Maria Grazia Valsecchi, Ph.D.

Professor Medical Statistics
Centre of Biostatistics for Clinical Epidemiology
Department of Clinical Medicine and Prevention
University of Milano-Bicocca, Milan, Italy

Julie M. Gastier-Foster, Ph.D.

Director, Cytogenetics/Molecular Genetics Laboratory
Associate Professor-Clinical College of Medicine, Ohio State University
Nationwide Children's Hospital, Columbus Ohio

**Minimal Residual Disease (MRD) as a Surrogate Endpoint
in Acute Lymphoblastic Leukemia (ALL) Workshop
Meeting Roster
April 18, 2012**

FDA White Oak Campus, Building 31, the Great Room,
White Oak Conference Center
(Rm. 1503), Silver Spring, MD

Nicola Gökbuget, M.D.

Head of Study Center, University Cancer Center
Goethe University Hospital
Department of Medicine II
Hematology/Oncology
Frankfurt, Germany

Stephen Hunger, M.D.- Co-Chair

Ergen Family Chair in Pediatric Cancer and Director, Center for Cancer and Blood Disorders
Children's Hospital Colorado
Chief, Section of Pediatric Hematology/Oncology/Bone Marrow Transplantation
Professor of Pediatrics, Univ. of Colorado School of Medicine

Michael Link

President, American Society of Clinical Oncology
Professor in Pediatric Cancer, Stanford University

Wendy Stock, M.D.

Professor of Medicine
University of Chicago Comprehensive Cancer Center

Jerald P. Radich, M.D.

Associate Professor, Medial Oncology Division
University of Washington School of Medicine

Elizabeth Raetz, M.D.

Associate Professor; Fellowship Dir of Pediatric Hematology/Oncology
Department of Pediatrics (Oncology Division)
NYU Pediatric Hematology Oncology

Jacques J.M. van Dongen, M.D., Ph.D.

Department of Immunology
Erasmus Medical Center, University Medical Center Rotterdam, the Netherlands

James Whitlock, M.D.

Division Head, Haematology/Oncology
Women's Auxiliary Millennium Chair in Haematology/Oncology
Director, Garron Family Cancer Centre
Senior Associate Scientist, Child Health Evaluative Sciences Program, Research Institute
The Hospital for Sick Children
Professor of Paediatrics, University of Toronto

**Minimal Residual Disease (MRD) as a Surrogate Endpoint
in Acute Lymphoblastic Leukemia (ALL) Workshop
Meeting Roster
April 18, 2012**

FDA White Oak Campus, Building 31, the Great Room,
White Oak Conference Center
(Rm. 1503), Silver Spring, MD

Brent Wood, M.D., Ph.D.
Department of Laboratory Medicine
University of Washington

FDA

Richard Pazdur, M.D.
Director
Office of Hematology and Oncology Products (OHOP)
Office of New Drugs, CDER, FDA

Gregory Reaman, M.D.- Co Chair
Associate Director
Office of Hematology and Oncology Products (OHOP)
Office of New Drugs, CDER, FDA

Albert Deisseroth, M.D., Ph.D.
Medical Team Leader
Division of Hematology
Office of Hematology and Oncology Products (OHOP)
Office of New Drugs, CDER, FDA

Elizabeth Mansfield, Ph.D.
Director, Personalized Medicine Staff
Office of *In vitro* Diagnostic Device Evaluation and Safety (OVI), CDRH, FDA

Mark Rothmann, Ph.D.
Office of Translational Science
Office of Biometrics/DBV
Office of New Drugs, CDER, FDA

Marc Walton, M.D., Ph.D.
Associate Director
Office of Translational Sciences